Redeye updates its estimates and valuation following Freemelt’s Q3 report, which came in above our e...
Redeye makes downward estimate revisions following Climeon’s Q3 report, mainly driven by the absence...
Redeye updates on Embracer ahead of Q2-results (due 14 November) where we expect another quarter wit...
Q3 numbers in line with estimates Guidance trimmed, but limited impact on estimates All share bid li...
Q3: EBITDA of ~NOK 12m, Q4 likely flat New targets achievable, but lower range more likely Recovery ...
Redeye gives a brief comment on today’s news that the first patient has been included in the ELC-301...
Hanza rapporterade ett kvartal över Analysguidens förväntan.
Analyst Group has entered into an agreement with Irisity on commissioned research, including e.
Redeye comments on Climeon’s Q3 figures that posted a variety of deviations from our estimates.
Q-linea continues improving the pipeline of prospects of various stages, from entering tenders to cl...
Redeye gives its initial comments on the Q3 2024 report from Scandinavian ChemoTech, which was mostl...
Q3 EBITDA of 15.2m, in line with ABGSCe of USD 15.3m Small downward revisions to guidance Q3 much as...
Redeye comments on Freemelt’s Q3 results, which were roughly in line with expectations in terms of s...
NoHo Partners reported Q3 EBIT of EUR 9.9m (+14% y/y), 5% below Vara Research consensus and 11% belo...
Redeye states that the CoinShares Q3 2024 report was solid, with asset management fees above RRe, wh...
